title: Plasma adiponectin and resistin levels as predictors of mortality in patients with acute myocardial infarction: data from infarction prognosis study registry.
abstract: BACKGROUND
  Adiponectin and resistin, which have counteracting effects, are suggested to be associated with inflammation and atherosclerosis. The relationship between their levels and prognosis in high risk patients is, however, still unclear. The aim of this study was to evaluate the prognostic values of these adipokines in patients with acute myocardial infarction (MI).
  
  
  METHODS
  Adiponectin and resistin levels were measured at acute phase of MI in 397 consecutive patients. All patients were followed-up for the occurrence of all-cause and cardiovascular mortalities. Predictors for all-cause and cardiovascular mortalities were analyzed by Cox proportional hazard model.
  
  
  RESULTS
  During the mean follow-up period of 12 months, 28 (7.1%) patients died. Unadjusted all-cause mortality rate was significantly higher in patients with high tertiles of adiponectin (P=0.002) and resistin (P=0.002) levels. After controlling of clinical and laboratory variables, age [95% confidence interval (CI): 1.20-2.83, P=0.006], adiponectin (95% CI: 1.01-1.22, P=0.040), resistin (95% CI: 1.06-2.33, P=0.025), and statin use (95% CI: 0.15-0.83, P=0.017) were found to be independent predictors of all-cause mortality. For cardiovascular mortality, only age (95% CI: 1.33-3.25, P=0.001) and renal insufficiency (95% CI: 1.52-12.22, P=0.006) were independent predictors.
  
  
  CONCLUSIONS
  High plasma adiponectin and resistin levels were predictors for all-cause mortality independent of other risk factors in patients with acute MI. These results confirmed and extended the positive correlations between these adipokines and mortality to a population consisting exclusively of MI.
authors.affiliation: Cardiology Division, Yonsei University College of Medicine, Seoul, Korea.
authors.forename: Sang-Hak
authors.initials: SH
authors.lastname: Lee
authors.forename: Jong-Won
authors.initials: JW
authors.lastname: Ha
authors.forename: Jung-Sun
authors.initials: JS
authors.lastname: Kim
authors.forename: Eui-Young
authors.initials: EY
authors.lastname: Choi
authors.forename: Sungha
authors.initials: S
authors.lastname: Park
authors.forename: Seok-Min
authors.initials: SM
authors.lastname: Kang
authors.forename: Donghoon
authors.initials: D
authors.lastname: Choi
authors.forename: Yangsoo
authors.initials: Y
authors.lastname: Jang
authors.forename: Namsik
authors.initials: N
authors.lastname: Chung
mesh_terms: D052242:Adiponectin / Q000097:blood; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000401:mortality* / Q000628:therapy; D011237:Predictive Value of Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D011446:Prospective Studies; D012042:Registries; D052243:Resistin / Q000097:blood*; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D015854:Up-Regulation
chemical_list: C499918:ADIPOQ protein, human; D052242:Adiponectin; D015415:Biomarkers; C499624:RETN protein, human; D052243:Resistin